ArticleCurrent treatment options in neurology2013
New treatment options for lennox-gastaut syndrome.
Article in Current treatment options in neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 20 citations in OpenAlex.
- Genetic basis of pediatric epilepsy syndromes.Experimental and therapeutic medicine · 2017Article
- Treatment-resistant Lennox-Gastaut syndrome: therapeutic trends, challenges and future directions.Neuropsychiatric disease and treatment · 2017Review
- Epileptic encephalopathies: new genes and new pathways.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2014Review
- Experience in the use of clobazam in the treatment of Lennox-Gastaut syndrome.Therapeutic advances in neurological disorders · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementLennox-Gastaut syndrome (LGS) is one of the most difficult epilepsy syndromes to treat, and many children are refractory to standard treatment regimens. Valproic acid, topiramate, and lamotrigine are considered first-line therapies. Newer agents, including clobazam and rufinamide, are promising additions to the current treatment options. The ketogenic diet and vagus nerve stimulation are important adjuncts, with increasing evidence to support their use. Corpus callosotomy should be considered in refractory cases. Finally, focal resective surgery should be considered in patients with lesional disease, although for most patients with LGS this is unlikely to be the case.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.